Foot Locker (FL) will be issuing its third quarter earnings press release after the US markets close on Tuesday, November 20. It’s a do or die situation for Foot Locker, which is already hurt by the slowdown in the industry as well as competition from its major supplier Nike (NKE), online retail giant Amazon (AMZN) and other apparel and shoe retailers.
Consensus views the company to post income of $0.92 per share on revenue of $1.85 billion. This compares with the income of $0.87 per share on revenue of $1.87 billion in the last year’s third quarter.
For the second quarter ended August 4, 2018, the New York-based specialty athletic retailer reported earnings of $0.75 per share on revenues of $1.78 billion, both surpassing the analysts’ forecast. Comp-store sales grew 0.5%.
The company has beaten the analysts’ expectations in the past two quarters. Apart from the Q3 numbers, the investing community will also look out how the company guides for the final quarter of 2018, given the importance of the holiday season. The strong economy, lower unemployment and higher consumer confidence could have boosted Foot Locker’s performance in the third quarter and it might continue in Q4 also.
Investors of Foot Locker’s key suppliers like Nike, Under Armour (UAA) and Adidas also would be watching keenly on the Foot Locker’s results.
Foot Locker’s peer Dick’s Sporting Goods (DKS) is expected to issue its quarterly results on November 28. On Tuesday, November 20, other notable retailers like Best Buy (BBY), Target (TGT), Kohl’s Corp. (KSS) and Ross Stores (ROST) will also be reporting their quarterly results.
The stock, which declined 4.07% at $48.81 on Monday and inched up during the after-market session, had an average analysts’ rating of “Buy” and a price target of $56.71. Shares of the Foot Locker have gained 4% in the year-to-date period and 20% in the past 52-weeks.
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key